Neuropsychopharmacology
May 5, 2020
Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov et al.
66 citations
For most psychiatric disorders, including alcohol use disorder (AUD), approved pharmacological treatments are limited in their effectiveness, and new drugs that can easily be translated into the clinic are needed. Currently, great hope lies in the potential of psychedelics to effectively treat AUD. The primary hypothesis is that a single session of psychedelic-guided psychotherapy can restore...
Psychopharmacology
May 1, 2020
Toby Lea, Nicole Amada, Henrik Jungaberle et al.
The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. This paper examined subjective experiences of microdosing...
Pharmacology, Biochemistry, and Behavior
April 22, 2020
Jeffrey M. Witkin, J. Kranzler, K. Kaniecki et al.
33 citations
Substance abuse disorder continues to have devastating consequences for individuals and society and current therapies are not sufficient to provide the magnitude of medical impact required. Although some evidence suggests the use of ketamine in treating various substance use related- symptoms, its adverse event profile including dissociation, dysphoria, and abuse liability limit its potential...
Proceedings of the National Academy of Sciences
April 13, 2020
Morten L. Kringelbach, Josephine Cruzat, Joana Cabral et al.
326 citations
Significance In a technical tour de force, we have created a framework demonstrating the underlying fundamental principles of bidirectional coupling of neuronal and neurotransmitter dynamical systems. Specifically, in the present study, we combined multimodal neuroimaging data to causally explain the functional effects of specific serotoninergic receptor (5-HT 2A R) stimulation with psilocybin...
Romanian Journal of Psychiatry & Psychotherapy
March 31, 2020
Tiberiu Constantin Ionescu, Ionut-Stelian Popa, Alin Chiriac et al.
Objectives Post-traumatic stress disorder (PTSD) is a severe psychiatric disorder, with disabling potential and chronic evolution, that occurs at some people due to exposure to a specific traumatic event or threats of death, serious injury or sexual violence. Currently, psychotherapy is accepted as one of the most effective methods of treating PTSD. Incomplete clinical response as well as...
Journal of Evolutionary Psychology
March 30, 2020
Claire Wilson, Trevor Millar, Zak Matieschyn
11 citations
Abstract Ibogaine is a naturally occurring psychedelic medicine with anti-addictive properties. While research on ibogaine is limited, several observational studies have shown ibogaine can mitigate opioid withdrawal, as seen with reductions in clinical and subjective opioid withdrawal scores and reduced drug use severity (Noller, Frampton, & Yazar-Klosinski, 2018; Brown & Alper 2018)....
Psychiatric News
March 20, 2020
Katie O’connor
Though the field is young, psychedelics appear to hold promise as a treatment for addiction, even as barriers to research persist. Researchers around the world are investigating how drugs such as LSD, MDMA (also known as ecstasy), ketamine, and psilocybin (the active ingredient in magic mushrooms) can treat patients with substance use disorders (SUD). Though there is still a lot to learn, early...
Frontiers in Pharmacology
March 18, 2020
Esther Papaseit, Marta Torrens, Mireia Ventura et al.
20 citations
2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2 A), 2B (5-HT2 B), and (5-HT2 C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic...
March 1, 2020
Adam Winstock, James W. Rucker
29 citations
Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...
PLoS One
February 21, 2020
Bheatrix Bienemann, Nina Stamato Ruschel, Maria Luiza Pesse Campos et al.
81 citations
Psilocybin, a substance mainly found in mushrooms of the genus psilocybe, has been historically used for ritualistic, recreational and, more recently, medicinal purposes. The scientific literature suggests low toxicity, low risk of addiction, overdose, or other causes of injury commonly caused by substances of abuse, with growing interest in the use of this substance for conditions such as...
Frontiers in Psychiatry
January 22, 2020
Earth Erowid, Fire Erowid, Albert Garcia‐romeu et al.
155 citations
While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential that psychedelics cause reductions in problematic substance use, and support additional clinical research on psychedelic-assisted treatment for SUD.
Frontiers in Psychiatry
January 21, 2020
Juan José Fuentes, Francina Fonseca, Matilde Elices et al.
176 citations
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a...
Addiction Science & Clinical Practice
January 19, 2020
Jennifer Rozylo, Keren Mitchell, Mohammadali Nikoo et al.
Abstract Background The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. Case presentation We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a...
Yakugaku Zasshi
2020
Masahiko Funada, Ken-Ichi Tomiyama
Cannabis use among the younger population in Japan has been steadily increasing. The aim of the present review is to highlight recent knowledge regarding the molecular mechanisms of action and health risks associated with cannabis and synthetic cannabinoid consumption. We investigated the effects of Δ9-tetrahydrocannabinol (THC) and synthetic cannabinoids on place conditioning in ICR mice. Both...
Journal of Studies on Alcohol and Drugs
2020
Mark Haden, Birgitta Woods
31 citations
OBJECTIVE: In academic settings around the world, there is a resurgence of interest in using psychedelic substances for the treatment of addictions, posttraumatic stress disorder, depression, anxiety, and other diagnoses. This case series describes the medical consequences of accidental overdoses in three individuals. METHOD: Case series of information were gathered from interviews, health...
European Addiction Research
2020
Franz Moggi, Deborah Schorno, Leila M. Soravia et al.
22 citations
<b><i>Background:</i></b> Attention deficit/hyperactivity disorder (ADHD), conduct disorder (CD), and sensation seeking (SS) have been consistently related to a higher risk of substance use (SU) and substance use disorder (SUD). <b><i>Objectives:</i></b> To investigate the relationship between ADHD and prevalence rates in males at age 20 and age 25, the initiation of SU and SUD after age 20,...
2020
Alberto Dubbini, Jacques Mabit, Matteo Politi
Objetivo. Este artículo tiene como objetivo ofrecer una descripción general del papel de la espiritualidad, de la fe y de las experiencias místicas en el tratamiento de los trastornos por uso de sustancias (TUS) presentando el caso de la comunidad terapéutica Takiwasi, donde se utilizan plantas psicoactivas, y considerando otras terapias pertenecientes a las medicinas complementarias y...